Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AsfiledCriticalNovo Nordisk As
Publication of AR123039A1publicationCriticalpatent/AR123039A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Se describen coagonistas peptídicos de los receptores de GLP1 y GIP humanos, sus derivados de acción prolongada y sus usos médicos en el tratamiento y/o prevención de la obesidad, la diabetes y/o enfermedades hepáticas.Peptide coagonists of human GLP1 and GIP receptors, their long-acting derivatives, and their medical uses in the treatment and/or prevention of obesity, diabetes, and/or liver diseases are disclosed.
ARP210102059A2020-07-222021-07-22
COAGONISTS OF GLP-1 AND GIP RECEPTORS
AR123039A1
(en)
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER, INCLUDING IMMUNE CHECKPOINT INHIBITOR AND FUSION PROTEIN INCLUDING IL-2 PROTEIN AND CD80 PROTEIN